Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million

Merck (MRK) to Buy Private Biotech Tilos for Up to $773M

Abbott Labs

Johnson & Johnson

Novartis

Pfizer

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

Five Health Care Stocks Gurus Are Buying

Keeping in line with the biotech M&A frenzy seen for much of the year, Merck & Co., Inc. announced a deal Monday to buy Tilos Therapeutics.

Merck Strikes $773M Deal For Privately Held Tilos Therapeutics

Merck & Co. Inc. said Monday it was buying privately held biopharmaceutical company Tilos Therapeutics, in a deal that could be valued at up to $773 million.

Merck to buy cancer-treatment biotech Tilos Therapeutics for up to $773 million

Merck’s S&P CFRA, three-year forward CAGR of 12%, is good and will give you good growth with the increasing world economy and population.

Buy Merck For Growth And Its Good Pipeline Of Breakthrough Drugs

Merck’s (NYSE:MRK) oncology drugs’ revenue could grow at a CAGR of 10.3% from $8.24 billion in 2018 to $10.95 billion in 2021, according to Trefis estimates. This growth will likely be led by higher sales of Keytruda, as well as higher alliance revenues from Lynparaza and Lenvima.

How Much Can Merck's Oncology Drugs' Revenue Grow Over The Next Three Years?

AstraZeneca

Bristol-Myers

Eli Lilly

Roche Holding AG

Sanofi

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

Cisco Systems

Chevron

Microsoft

Walmart

Despite severe market volatility, the blue-chip index of Wall Street has provided double-digit returns to investors so far this year.

5 Top Dow Stock Gainers of Past Month Still Holding Momentum

Amgen

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

Merck announced long-term 5-year data for Keytruda, which showed that patients increased overall survival by 5X fold, to 23.2% in treatment naive advanced lung cancer patients.

Merck Makes Case For Keytruda In Lung Cancer After Latest Long-Term Survival Data

Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)

Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication

Alexion Pharma

AMAG Pharmaceuticals

Palatin Technologies

Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.

3 Drug Stocks That Could Win From Key FDA Approvals in June

Tech stocks were hammered on regulatory concerns. Meanwhile, Cypress Semiconductor is being acquired, and Merck reported strong survival rates in a lung cancer trial.

Merck reports fivefold improvement in lung cancer survival

Merck continues to see the benefit of growing Keytruda sales as legacy sales are coming in flat, after a long time of steady declines.

Merck - Growth Showing Up, Pipeline Filling Up

Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates

Merck's Keytruda Improves 5-Year Survival in Lung Cancer

McDonald's

Travelers

UnitedHealth Group

Just five Dow components were poised for May gains Thursday afternoon, a reflection of the effect the trade war is having on Wall Street.

Only five Dow stocks have gained in May as trade war drags on

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Why Is Merck (MRK) Up 0.8% Since Last Earnings Report?

Merck's shares are up 6.2% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

Merck (MRK) Up This Year So Far: Will the Momentum Continue?

Boston Scientific

U.S. equities are mostly higher in post-holiday trading on Tuesday, as investors are looking for stocks to buy.

4 Drug and Health Stocks Pushing Higher  

Two big pharma titans are battling for supremacy in the field of oncology immunotherapy.

Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

The acquisition can strengthen Merck's presence in the field of renal cell carcinoma and bolster its cancer drug portfolio.

Merck buys Peloton Therapeutics to expand its kidney cancer treatment portfolio

Dow Jones component Merck will spend up to $2.2 billion to buy privately held biotech Peloton Therapeutics for its cancer treatments. Peloton's latest-stage effort is a kidney cancer drug.

Merck To Acquire Cancer Biotech In Deal Worth Up To $2.2 Billion

Merck & Co., Inc. announced an agreement Tuesday to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion in if certain regulatory and sales milestones are reached.

Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B

U.S. drugmaker Merck & Co Inc on Tuesday agreed to buy Peloton Therapeutics Inc for $1.05 billion in cash, gaining access to the privately held company's lead kidney cancer drug candidate.

Merck buys Peloton to expand its kidney cancer treatment portfolio

Merck & Co Inc said on Tuesday it would buy Peloton Therapeutics Inc for $1.05 billion in cash to gain access to the privately held company's renal cancer drug candidate.

News for Merck Stock (MRK)